Abstract
GIST is the most common mesenchymal tumor of the gastrointestinal tract. Clinical trials or targeted therapies are recommended for c-kit and PDGFRA wild-type GIST patients who are unable to obtain multi-target protein tyrosine kinase inhibitors therapy. Thus, the identification of targetable mutations will gain new insights into the etiology of c-kit and PDGFRA wild-type GIST.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
